Last reviewed · How we verify

NCT06116006: BIROBONIRS

fNIRS Study of Effort-dependent Brain Activations During Pointing Movements of the Upper Limb in Post-stroke Patients and Healthy Subjects

Completed NA Last updated 18 March 2026
What this trial tests

NA trial testing Upper limb pointing movements in 3 experimental conditions in Stroke in 64 participants. Completed in 2 February 2024.

Timeline
15 January 2024
Primary endpoint
2 February 2024
2 February 2024

Quick facts

Lead sponsorClinique Les Trois Soleils
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment64
Start date15 January 2024
Primary completion2 February 2024
Estimated completion2 February 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Clinique Les Trois Soleils

Who can join

18 and older, any sex, with Stroke or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Following a stroke, as part of neurorehabilitation, the intensity of effort is important to promote neural changes and stimulate motor recovery. There are few studies concerning the cortical activity involved at different levels of intensity during upper limb motor training. Objective: To investigate cortex activation while walking an exoskeleton with 4 levels of guidance force in healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Clinique Les Trois Soleils trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing